Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

Gemcitabine 54130-nm albumin-bound paclitaxel 29Magnetic Resonance Spectroscopy 21Taxes 18Fluorouracil 18Specimen Handling 17Oxaliplatin 17Leucovorin 17Drug Therapy 17Albumin-Bound Paclitaxel 17Irinotecan 14pembrolizumab 13Cyclophosphamide 11Blood Specimen Collection 11Biopsy 11fludarabine 10Radiosurgery 9irinotecan sucrosofate 8folfirinox 6Magnetic Resonance Imaging 6Cetuximab 6Bevacizumab 6dehydroftorafur 5Surveys and Questionnaires 5Nivolumab 5Endoscopic Ultrasound-Guided Fine Needle Aspiration 5sintilimab 4olaparib 4balstilimab 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Neoplasms × CX 5461 × Clear all
NCT04890613 2026-04-28

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Senhwa Biosciences, Inc.

Phase 1 Recruiting
52 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡